Estland - Estlands - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 17,5mg 0.35ml 0.35ml 6tk; 17,5mg 0.35ml 0.35ml 1tk; 17,5mg 0.35ml 0.35ml 15tk; 17,5mg 0.35ml 0.35ml 24tk; 17,5mg 0.35ml 0.35ml 10tk; 17,5mg 0.35ml 0.35ml 2tk; 17,5mg 0.35ml 0.35ml 12tk; 17,5mg 0.35ml 0.35ml 5tk; 17,5mg 0.35ml 0.35ml 4tk; 17,5mg 0.35ml 0.35ml 11tk

Estland - Estlands - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 20mg 0.4ml 0.4ml 1tk; 20mg 0.4ml 0.4ml 5tk; 20mg 0.4ml 0.4ml 11tk; 20mg 0.4ml 0.4ml 10tk; 20mg 0.4ml 0.4ml 4tk; 20mg 0.4ml 0.4ml 6tk; 20mg 0.4ml 0.4ml 2tk; 20mg 0.4ml 0.4ml 15tk; 20mg 0.4ml 0.4ml 14tk; 20mg 0.4ml 0.4ml 12tk

Estland - Estlands - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 10mg 0.2ml 0.2ml 11tk; 10mg 0.2ml 0.2ml 14tk; 10mg 0.2ml 0.2ml 4tk; 10mg 0.2ml 0.2ml 2tk; 10mg 0.2ml 0.2ml 24tk; 10mg 0.2ml 0.2ml 10tk; 10mg 0.2ml 0.2ml 1tk; 10mg 0.2ml 0.2ml 15tk

Estland - Estlands - Ravimiamet

jubilant pharmaceuticals nv - okskarbasepiin - õhukese polümeerikattega tablett - 300mg 200tk; 300mg 60tk; 300mg 90tk; 300mg 20tk; 300mg 10tk; 300mg 30tk; 300mg 50tk

Estland - Estlands - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 15mg 0.3ml 0.3ml 4tk; 15mg 0.3ml 0.3ml 2tk; 15mg 0.3ml 0.3ml 10tk; 15mg 0.3ml 0.3ml 6tk; 15mg 0.3ml 0.3ml 14tk; 15mg 0.3ml 0.3ml 12tk; 15mg 0.3ml 0.3ml 24tk; 15mg 0.3ml 0.3ml 15tk; 15mg 0.3ml 0.3ml 5tk; 15mg 0.3ml 0.3ml 11tk

Estland - Estlands - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 7,5mg 0.15ml 0.15ml 6tk; 7,5mg 0.15ml 0.15ml 24tk; 7,5mg 0.15ml 0.15ml 10tk; 7,5mg 0.15ml 0.15ml 11tk; 7,5mg 0.15ml 0.15ml 2tk; 7,5mg 0.15ml 0.15ml 5tk; 7,5mg 0.15ml 0.15ml 12tk; 7,5mg 0.15ml 0.15ml 14tk; 7,5mg 0.15ml 0.15ml 4tk; 7,5mg 0.15ml 0.15ml 1tk

Estland - Estlands - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 22,5mg 0.45ml 0.45ml 14tk; 22,5mg 0.45ml 0.45ml 1tk; 22,5mg 0.45ml 0.45ml 10tk; 22,5mg 0.45ml 0.45ml 2tk; 22,5mg 0.45ml 0.45ml 11tk; 22,5mg 0.45ml 0.45ml 12tk

Europese Unie - Estlands - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muud närvisüsteemi ravimid - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Europese Unie - Estlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant võib kasutada monoteraapiana või kombinatsioonis metotreksaadiga. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Europese Unie - Estlands - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.